INDIANAPOLIS, May 28, 2024
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will
participate in the Goldman Sachs 45th Annual Global Healthcare
Conference on June 10,
2024. Patrik Jonsson, executive vice president, president of
Lilly Diabetes and Obesity, and president of Lilly USA, will participate in a fireside chat at
4 p.m. Eastern time.
A live audio webcast will be available on the "Webcasts &
Presentations" section of Lilly's Investor website at
https://investor.lilly.com/webcasts-and-presentations. A replay of
the presentation will be available on this same website for
approximately 90 days.
About Lilly
Lilly is a medicine company turning
science into healing to make life better for people around the
world. We've been pioneering life-changing discoveries for nearly
150 years, and today our medicines help more than 51 million people
across the globe. Harnessing the power of biotechnology, chemistry
and genetic medicine, our scientists are urgently advancing new
discoveries to solve some of the world's most significant health
challenges: redefining diabetes care; treating obesity and
curtailing its most devastating long-term effects; advancing the
fight against Alzheimer's disease; providing solutions to some of
the most debilitating immune system disorders; and transforming the
most difficult-to-treat cancers into manageable diseases. With each
step toward a healthier world, we're motivated by one thing: making
life better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow
us on Facebook, Instagram and LinkedIn. F-LLY
Refer
to:
|
Jordan Bishop;
jordan.bishop@lilly.com; 317-473-5712 (Media)
|
|
|
Joe Fletcher;
jfletcher@lilly.com; 317-296-2884 (Investors)
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-goldman-sachs-45th-annual-global-healthcare-conference-302156198.html
SOURCE Eli Lilly and Company